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The calpain family, and their endogenous inhibitor calpastatin, has been implicated in cancer progression, and recent in vitro
data have indicated a role in trastuzumab resistance. The aims of our study were to examine expression levels of calpastatin,
calpain-1 and calpain-2 in breast tumours from patients treated with trastuzumab following adjuvant chemotherapy to
determine their potential as biomarkers to predict therapeutic response. The expression of calpastatin, calpain-1 and calpain-
2 was determined, using immunohistochemistry (IHC), in tumours from a series of 93 patients with primary breast cancer
treated with surgery and adjuvant chemotherapy with or without trastuzumab followed by trastuzumab to complete 1 year of
therapy. IHC was performed using tissue microarrays constructed from cores taken from intratumour and peripheral tumour
areas. Expression was correlated with clinicopathologic variables and patient outcome. Calpastatin expression was correlated
with Nottingham prognostic index (p 5 0.003) and lymph node status (p 5 0.007). Trastuzumab resistance was defined as
disease relapse during therapy. Calpain-1 expression is associated with relapse-free survival (p 5 0.001) and remained
significant in multivariate analysis accounting for confounding pathological and treatment variables (hazard ratio 4.60, 95%
confidence interval 1.05–20.25; p 5 0.043). Calpain-1 may be a useful biomarker to predict relapse-free survival in breast
cancer patients treated with adjuvant trastuzumab and chemotherapy. A larger verification study is warranted.
HER2 belongs to the family of human epidermal growth
factor receptors (EGFR, ErbB or HER), which has three other
members: HER1 (EGFR), HER3 and HER4, and functions as
receptor tyrosine kinases. Activation of the HER1, 3 and 4
occurs via a number of ligands promoting dimerisation.
HER2 has no direct ligand and acts as a coreceptor by prefer-
ential formation of heterodimers with other family members.1
In breast cancer, a mutation leading to overexpression, or
altered receptor structure, can cause the formation of hetero-
dimer and homodimer, which result in overactivation and
uncontrolled cellular growth (reviewed in Ref. 2). Amplifica-
tion of HER2 occurs in 15–30% of breast cancers and results
in a more aggressive phenotype.3 Normal HER2 signalling
can act via phosphorylation of phosphatidylinositol kinase-3
(PI3K) or through induction of Ras and affects cell survival
and cell cycle progression.4 Trastuzumab (Herceptin) is
a humanised anti-HER2 monoclonal antibody, approved
for use in HER2-positive breast cancer that significantly
improves disease-free survival after adjuvant chemotherapy.5–7
Trastuzumab has been postulated to exert antitumour effects
via a number of potential mechanisms including antibody-
dependent cellular cytotoxicity, inhibition of signal transduc-
tion, proteolytic cleavage of HER2, angiogenesis and DNA
repair.4 Trastuzumab improves the outcome for HER2-positive
breast cancers; however, a number of patients can develop
resistance to treatment. Certain tests have shown efficacy in
predicting response to trastuzumab therapy in patients with
metastatic cancer such as the measurement of serum levels of
the extracellular domain of HER2,8 and there is evidence that
low PTEN expression can predict resistance to trastuzumab in
patients with metastatic disease treated with trastuzumab and
taxane.9,10 However, PTEN expression does not reliably pre-
dict response in patients treated with trastuzumab containing
neoadjuvant chemotherapy.11
The calpains and their endogenous inhibitor calpastatin
have a role in a number of disease pathologies, notably car-
cinogenesis. The calpain family has been implicated in
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various cellular processes including cell differentiation, tran-
scriptional regulation, cytokine processing, migration and
apoptosis.12,13 The calpains are calcium-dependent cysteine
proteases including calpain-1 and -2 (EC3.4.22.52 and EC
3.4.22.53). Activation of calpain-2 can occur via the signal-
regulated kinase/mitogen-activated protein (ERK/MAPK)
pathway, whereas calpain-1 can be activated by physiologi-
cal calcium levels.14 Dephosphorylation by protein phospha-
tase 2A has been shown to reduce activity of calpain-1 and
-2 in vitro.15 In cancer, calpain-2 has been implicated in the
in vitro formation of invadopodia, which are associated with
extracellular matrix degradation and increased invasive
potential.16
Calpain has been implicated in HER2 signalling pathways
in a number of studies. Calpain-2 can be activated by EGFR
through the ERK/MAPK pathway by direct phosphorylation
of calpain.17,18 HER2 overexpression results in activation of
the Akt and ERK pathways. The Akt pathway results in a
number of events important in tumourigenesis such as sig-
nalling through the mTOR pathway. Importantly, HER2 has
been shown to induce NFjB through the AKT pathway,
which is maintained by calpain-mediated cleavage of the IjB
kinase complex.19 Recent evidence has indicated a further
role for calpain in trastuzumab-resistant breast cancer. Kul-
karni et al. investigated the influence of calpain-1 in trastuzu-
mab-treated HER2-positive breast cancer in vitro.20 Their
data suggested that calpain-1 is activated following trastuzu-
mab treatment and cleaves HER2 to disrupt signalling. In
addition, they showed that trastuzumab-sensitive cells have
higher calpain-1 activity than resistant cells; however, trastu-
zumab-resistant cells become dependent on calpain-1 activity
for survival.
Interestingly, calpain is implicated in a number of interre-
lated pathways. For example, integrin engagement can cause
focal adhesion kinase (FAK) phosphorylation, which results
in ERK activation of calpain-1 to cleave FAK, which results
in enhanced cell motility.21 FAK, like phosphatidylinositol
(3,4,5)-triphosphase (PIP3), can be dephosphorylated by
PTEN indicating pathway overlap.
The aims of our study were to (i) analyse the expression
pattern of calpastatin, calpain-1 and calpain-2 in HER2-
positive breast cancer and (ii) to determine if the expression
of these proteins can predict relapse-free survival in HER2-




Our study is reported in accordance with REMARK criteria.22
The expression of calpastatin, calpain-1 and calpain-2 was
investigated using a tissue microarray (TMA) of 93 patients
with primary breast cancer treated at Nottingham University
Hospitals, King’s Mill Hospital or Derby Hospitals between
June 2004 and December 2009 with a median follow-up time
of 30 months. Clinicopathologic variables of the cohort are
recorded in Table 1. Patients were all treated with trastuzu-
mab following surgery and chemotherapy. Trastuzumab
treatment was given on a 3 weekly regimen for 52 weeks.
Chemotherapy consisted of six cycles of 3 weekly fluorouracil
(500 mg/m2), epirubicin (100 mg/m2) and cyclophosphamide
(500 mg/m2) (FEC) combination (n ¼ 53) or FEC-T consist-
ing three cycles of FEC followed by three cycles of trastuzu-
mab with concurrent docetaxel (100 mg/m2) per 3 weeks
when patients were in a high-risk prognostic group according
to local guidelines (n ¼ 40). Patients with oestrogen receptor
expression were offered adjuvant hormonal therapy (n ¼ 40)
following chemotherapy, and the majority of patients
received adjuvant radiotherapy (n ¼ 78). Treatment resist-
ance was defined as relapse during therapy, and relapse-free
survival was defined as the date from diagnosis to relapse
with a mean relapse-free survival of 32 months; median
survival for the group was not reached. Formalin-fixed paraf-
fin-embedded tissue was used to create the TMA with one
core per patient taken from intratumour and peripheral
tumour areas. All patients had HER2 expression determined
by IHC, and fluorescence in situ hybridisation was performed
on cases with a score of 2þ by IHC. At the end of the
Table 1. Clinicopathologic variables of patient sample cohort
Variables Number (n 5 93)
Age (years) 54.88 6 9.57


















Continuous data are shown as mean 6 standard deviation. Oestrogen
receptor (ER) status was positive with an H-score above 10. Age had a
minimum value of 30.7 and a maximum value of 74.8 years. Tumour
size had a minimum of 2 and a maximum of 90 mm. Nottingham
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follow-up period, there had been one death, and 12 patients
suffered a recurrence.
TMA construction and immunohistochemistry
Breast cancer TMAs were prepared.23 0.6 mm tissue cores
from both intratumour and peripheral tumour areas were
placed into a single recipient paraffin block. Four-micron sec-
tions of the TMA were mounted on poly-L-lysine-coated
slides. IHC was performed on the TMA slides, which were
initially deparaffinised in histolene followed by rehydration in
a series of ethanol baths (100, 90, 70, 50 and 30% in water).
Antigen retrieval was performed in 0.01 mol/L sodium citrate
buffer (pH 6) in a microwave, 750 W for 10 min followed by
400 W for 10 min. Endogenous peroxidase activity was
blocked over 10 min in 0.01% hydrogen peroxide in metha-
nol. Primary antibodies, mouse anti-calpastatin (1:20,000),
mouse anti-calpain-1 (1:5,000) and rabbit anti-calpain-2
(1:5,000) (all Chemicon, MA), were diluted in blocking serum
and applied to the tissue for 1 hr at room temperature. Stain-
ing was achieved using the Vectastain Elite ABC kit (univer-
sal), containing blocking serum, biotinylated secondary anti-
body and ABC reagent (Vector Laboratories, Peterborough,
UK). Immunohistochemical reactions were developed with
3,30-diaminobenzidine as the chromogenic peroxidase sub-
strate (Dako, Glostrup, Denmark). Sections were then coun-
terstained with Gills formula Haematoxylin (Vector Labora-
tories), dehydrated and fixed in histolene before mounting
with DPX. Breast tumour composite sections, which com-
prised of six Stage 1 breast tumours of Grade 1 to 3, were
included as positive and negative controls with each run,
with the negative control having primary antibody substi-
tuted for PBS.
Assessment of staining was conducted, after scanning of
the slides with a Nanozoomer Digital Pathology Scanner
(Hamamatsu Photonics), at 20 magnification. The expression
of calpastatin, calpain-1 and calpain-2 in tumour cells was
manually assessed using an immunohistochemical H-score.
Staining intensity was assessed as: none (0), weak (1), medium
(2) and strong (3) over the percentage area of each staining in-
tensity. H-scores were calculated by multiplying the percentage
area by the intensity grade (H-score range: 0–300). Thirty
percent of slides were examined by a second independent asses-
sor blinded to scores and clinicopathologic criteria with good
concordance between both scorers (single measure intraclass
correlations greater than 0.8). An average H-score was gener-
ated by taking the mean of intratumour and peripheral tumour
area cores and dichotomised using X-tile for analysis.24 Average
scores were used for analysis because of the relatively small
sample size.
Statistical analysis
The distribution of data was assessed using the Kolmogorov–
Smirnov test for goodness of fit. The relationship between
categorised protein expression and clinicopathologic factors
was analysed using Pearson’s Chi-square test of association
(v2), where there were more than two variables e.g. grade, or
Fisher’s exact test in a 2  2 table. Overall disease-specific
survival curves were plotted according to the Kaplan–Meier
method, and significance was determined using the log-rank
test. Multivariate survival analysis was performed by
Cox proportional hazards analysis. Spearman rank order
correlations were performed to test the associations between
expression of proteins in intratumour and peripheral tumour
locations, and between different proteins. All differences were
deemed significant at the level of p < 0.05. Statistical analysis
was performed using SPSS 15.0 software.
Results
Immunohistochemistry
Tissue expression of calpastatin, calpain-1 and calpain-2 was
determined in a series of trastuzumab-treated patients. Cal-
pastatin, calpain-1 and calpain-2 demonstrated cytoplasmic
staining with some granularity and heterogeneity between
adjacent tumour cells, varying from weak to intense staining.
Calpastatin had a median H-score of 130 and a standard
deviation of 655; calpain-1 had a median value of 155 6 44,
and calpain-2 core staining had a median value of 165 6 45.
Representative staining patterns from intracore and periph-
eral core are displayed in Figure 1.
A marginal biological correlation was observed between the
tumour expression of calpastatin and calpain-2 (r ¼ 0.231,
p ¼ 0.027), but not between calpastatin and calpain-1 or
calpain-1 and calpain-2. Further relationships were explored
by examining the relationship between localisation of expres-
sion in tumour cores. Significant correlation was observed
between intratumour and peripheral tumour cores for calpas-
tatin (r ¼ 0.675, p < 0.001) and calpain-1 (r ¼ 0.391, p <
0.001) but not calpain-2 (r ¼ 0.028, p ¼ 0.808).
Relationship with clinicopathologic variables
Calpastatin, calpain-1 and calpain-2 H-scores were dicho-
tomised using X-Tile software into low and high immunoreac-
tivity and correlated with clinicopathologic criteria. X-tile-gen-
erated cut points were as follows: calpastatin had an H-score
cut point of 150 with 30 cases having a high score; calpain-2
had an H-score cut point of 165 with 50 cases having a high
score; calpain-1 had an H-score of 215 with 10 cases having a
high score. A small number of TMA cores were not assessed
because of missing cores or insufficient representative tumour.
Correlations with clinicopathologic criteria are shown in
Table 2 for the three markers. Calpastatin expression corre-
lated with Nottingham prognostic index (NPI) (p ¼ 0.003)
and lymph node status (p ¼ 0.007). No significant correla-
tions were observed with calpain-1 and calpain-2 expression.
The HER2 ratio (HER2/CEN-17) was determined for
78.5% (73/93) of cases using chromogenic in situ hybridisa-
tion, irrespective of IHC scoring value, and was tested for
correlation with calpastatin, calpain-1 and calpain-2 expression
using the Spearman rank correlation coefficient. Gene amplifi-
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expression correlated with the HER2 gene amplification ratio
(r ¼ 0.258, p ¼ 0.027). No correlation was observed between
calpain-1 or calpain-2 and HER2 gene amplification. HER2
IHC H-scores were also tested for correlation with calpastatin,
calpain-1 and calpain-2 expression using the Spearman rank
correlation coefficient. Calpastatin expression was correlated
with the level of HER2 expression (r ¼ 0.350, p ¼ 0.001), but
no correlation was observed with calpain-1 and calpain-2.
Relationship with clinical outcome
Resistance to trastuzumab therapy was determined as patient
relapse during therapy. The expression of calpastatin, calpain-1
and calpain-2 was correlated with relapse-free survival using
Kaplan–Meier survival curves. The expression of calpain-1 was
significantly associated with relapse-free survival (p ¼ 0.001),
with high expression indicating resistance to treatment (Fig. 2).
No correlation was observed for calpastatin or calpain-2 expres-
sion and relapse-free survival (Fig. 2). Multivariate Cox regres-
sion analysis was performed including potential confounding
factors such as tumour size, grade, lymph node status and ER
status with individual Kaplan–Meier log-rank statistics of p ¼
0.073, p ¼ 0.115, p ¼ 0.760 and p ¼ 0.062, respectively. In addi-
tion, a cohort of other treatment factors was included such as
type of surgery (wide local excision or mastectomy), adjuvant
hormonal and radiotherapy, anthracycline or anthracycline and
taxane chemotherapy and if chemotherapy was given in a neo-
adjuvant setting with individual Kaplan–Meier log-rank statistics
of p ¼ 0.060, p ¼ 0.054, p ¼ 0.086, p ¼ 0.600 and p ¼ 0.554,
respectively. Finally, a cohort including all possible confounding
factors, both pathological and treatment bias, was included in
multivariate Cox regression analysis. The expression of calpain-1
remained an independent marker for relapse-free survival with
inclusion of pathologic confounders in the multivariate model
(hazard ratio (HR) 4.265, 95% confidence interval (CI) 1.22–
14.95; p ¼ 0.023) but also of treatment setting (HR 4.434, 95%
CI 1.30–15.13; p ¼ 0.017); finally, expression of calpain-1 was
an independent marker of relapse-free survival including both
pathologic and treatment confounding variables (HR 4.603, 95%
CI 1.05–20.25; p ¼ 0.043) (Table 3). No other markers were
assessed by multivariate Cox regression as they did not correlate
with relapse-free survival as single markers using Kaplan–Meier
survival curves. No correlations with overall survival were possi-
ble as only one event occurred.
Simple tests of association using the Fisher’s exact test
were performed to assess the relationship between protein
Figure 1. Photomicrographs of representative staining at 10
magnification with 20 magnification inset panel with scale bar
representing 100 lm. Intratumour (a) and peripheral (b) tumour
high calpastatin staining from the same patient; intratumour
(c) and peripheral (d) tumour low calpastatin staining from the same
patient; intratumour (e) and peripheral (f) tumour high calpain-1
staining from the same patient; intratumour (g) and peripheral
(h) tumour low calpain-1 staining from the same patient;
intratumour (i) and peripheral (j) tumour high and moderate
calpain-2 staining from the same patient; intratumour (k) and
peripheral (l) tumour low calpain-2 staining from the same patient.
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expression and relapse. Expression of calpain-1 was corre-
lated with relapse status (p ¼ 0.003) with 6.2% (5/81) of
patients with low and 41.7% (5/12) of patients with high
expression having relapsed disease. None of the other
markers was correlated with relapse status (Table 2).
Interestingly, calpain-1 expression in the peripheral
tumour core appears to be more informative for relapse-free
survival than central tumour expression. By analysing each
group using Kaplan–Meier survival curves, calpain-1 in the
peritumoural area correlates with relapse-free survival (p ¼
0.014), but not intratumoural staining (p ¼ 0.247). It is
unclear why a difference between the location of expression
would play a role in treatment response.
Discussion
Our study investigated expression levels of calpastatin,
calpain-1 and calpain-2 in 93 HER2-positive primary breast
cancers treated with trastuzumab following adjuvant chemo-
therapy. The results show that expression of calpain-1 is able
to predict relapse-free survival in patients treated with












40 6 (6.5%) 0.383 1.000 0.684
>40 87 (93.5%)
Tumour size (cm)


















Negative 51 (54.8%) 0.126 0.503 0.531
Positive 42 (45.2%)
PR status




Relapse free 81 (87.1%) 0.192 0.003 0.766
Relapse 12 (12.9%)
Fisher’s exact (2  2) test was used to determine significance, except where marked by * whereby the Pearson’s Chi-square test of association
was used.
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trastuzumab independent of pathological and clinical treat-
ment variables (p ¼ 0.043).
The findings presented in our study are interesting in the
light of in vitro studies highlighting the role of calpain in
HER2 signalling.19,20,25 The recent study by Kulkarni et al.
implicated calpain-1 in resistance to trastuzumab treatment.20
Their results suggested that trastuzumab resistance is crit-
ically dependent on residual calpain activity through an
impaired activation of calpain. It is difficult to draw compari-
sons between our study and previous in vitro work as our
work examines calpain and calpastatin protein expression
levels before treatment. The level of calpain activity in these
specimens is unknown, although calpastatin expression may
function to estimate this to some extent. In addition, the
activity of calpain can be modulated by a number of factors
such as physiological concentrations of calcium-activating
calpain-1 and ERK/MAPK pathway activation of calpain-2.14
The data presented here show that high protein expression
levels of calpain-1 are indicative of treatment outcome, with
high expression levels correlating with a worse prognosis.
Calpain activity has been implicated in the response to a
number of therapeutic agents, such as cisplatin-induced apo-
ptosis in lung adenocarcinoma cells through Bid activation,26
and has also been shown to degrade the DNA repair enzyme
OGG1 in response to treatment.27 In addition, calpain-2 has
been implicated in androgen receptor proteolysis to the
constitutively active low-molecular-weight form in prostate
cancer resulting through activation by ERK1 and 2.28
Calpain-1 expression was tested in multivariate analysis
against other treatment variables; however, it is possible that
calpain-1 expression may be influenced by these other treat-
ment factors as well as trastuzumab alone. Calpain has been
Figure 2. Analysis of relapse-free survival by Kaplan–Meier analysis of expression of calpain-1, calpain-2 and calpastatin determined
by IHC. (a) Calpain-1 expression (83 patients low expression, 10 patients high expression); (b) calpain-2 expression (42 patients high
expression, 50 patients low expression); (c) calpastatin expression (63 patients high expression, 30 patients low expression). Calpain-1
expression is significantly associated with relapse-free survival (p ¼ 0.001), but calpain-2 and calpastatin are not.
Table 3. Multivariate Cox regression analysis showing calpain-1 expression, various pathological and clinical treatment variables and their
effects upon relapse-free survival
Multivariate Cox regression analysis
95.0% CI for Exp(B)
B SE Wald df Sig. Exp(B) Lower Upper
Calpain-1 expression 1.527 0.756 4.081 1 0.043 4.603 1.046 20.245
Type of surgery 0.613 0.767 0.639 1 0.424 0.542 0.120 2.435
Adjuvant radiotherapy 7.514 11.358 0.438 1 0.508 0.001 0.000 2538707
Adjuvant hormonal therapy 1.392 170.427 0.000 1 0.993 4.025 0.000 4.7E þ 145
Neoadjuvant/adjuvant chemotherapy 1.356 1.227 1.221 1 0.269 0.258 0.023 2.856
Chemotherapy regimen 0.829 0.812 1.041 1 0.308 2.291 0.466 11.256
Lymph node status 5.796 11.334 0.262 1 0.609 329.057 0.000 1E þ 012
Oestrogen receptor status 2.933 170.424 0.000 1 0.986 0.053 0.000 6.2E þ 143
Tumour grade 10.042 18.386 0.298 1 0.585 22965.297 0.000 1E þ 020
Tumour size 3.046 1.182 6.639 1 0.010 21.021 2.073 213.201
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implicated in various tumourigenic processes such as altered
adhesion and cellular migration. Previous work in our labora-
tory has established a link between calpastatin expression and
lymphovascular invasion (LVI). This correlation was not
made in our study as the data for IHC determination of LVI,
as opposed to H&E, were not available.29 In our study, cal-
pastatin expression was significantly associated with NPI and
lymph node status, with low levels of expression associated
with more aggressive disease. Although calpastatin expression
was associated with NPI, it was not associated with relapse-
free survival; this was not unexpected as in our study NPI
did not correlate with relapse-free survival (p ¼ 0.132).
The expression of calpastatin correlates with calpain-2
expression, but not with calpain-1 expression. A correlation
was not observed between calpain-1 and calpain-2 expression.
It is unclear why a correlation is observed between calpain-2
and calpastatin, but not calpain-1; however, both of these
enzymes have different activation requirements. In addition to
the proteins investigated in our study, it would be interesting
to investigate the activity of calpain. This might be possible
using antibodies against calpain-specific degradation products;
however, such reagents require further validation in human
malignancies such as cancer.30,31 It would also be of interest
to investigate other proteins that may be indicative of poor
trastuzumab treatment response such as PTEN.9,11 A differ-
ence in expression was noted between calpain-1 intratumour
and peripheral tumour cores used to determine the average
H-score reported, with peripheral tumour staining more
closely linked with relapse-free survival (p ¼ 0.014 and p ¼
0.247 for peripheral tumour and intratumour, respectively). It
is unclear what effect the tumour location of calpain-1 expres-
sion would play on response to treatment; however, the scores
between cores taken from peripheral tumour and intratumou-
ral areas had a statistically significant correlation (p < 0.001).
The definition of trastuzumab response in patients treated
with combination therapy is challenging; however, the results
of our preliminary study on a cohort of 93 patients present
an exciting indication that calpain-1 expression levels are sig-
nificantly associated with relapse-free survival in patients
treated with trastuzumab following adjuvant chemotherapy.
The median follow-up time in our study was 30 months;
therefore, more patients in our cohort will be expected to
relapse.32 Follow-up studies with larger patient cohorts with
longer clinical follow-up are required, incorporating an inves-
tigation of calpain-1 expression and the response to other
treatment modalities such as adjuvant chemotherapy alone.
In particular, it must be noted that calpain appears to impart
a more aggressive phenotype in various cancer models,
including increased cellular motility.21 Although a small
sample cohort, we have shown that expression of calpain-1 is
significantly associated with relapse-free survival of patients
treated with trastuzumab following adjuvant chemotherapy.
Interestingly, the opportunity exists that antibodies that esti-
mate the activity of calpain by the detection of specific degra-
dation products, in combination with antibodies detecting
calpain expression, may provide a useful tool in determining
those patients who will not respond well to trastuzumab
treatment following adjuvant chemotherapy. Calpain-1 may
be a clinically relevant biomarker to determine HER2-positive
patients who will relapse following trastuzumab therapy.
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